This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Sean Sheridan is a speaker during the session discussing the results of the survey including information pertaining to over a decade of prior surveys, revealing trends in dealmaking, including valuation by technology type and stage of development, detailed consideration of royalty components, milestones, sources, and more.
For more information on this event, click here.
Navigating payer challenges for rare disease treatments requires innovative approaches to evidence generation and pricing strategies. Our Life Sciences...
Access to medicine and healthcare services poses persistent challenges, especially in low-income regions with high out-of-pocket expenses. Pharmaceutical...
Join us for a CRA-moderated panel discussion with leaders in Digital Therapeutics. Learn how key players are reacting to emerging challenges, and which...
CRA is exhibiting at the conference at booth #2018. Matt Majewski presents his session titled “What is a Fair Price for a Rare Disease Therapy?”...
